You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tilelizumab

Showing 1 - 8 of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

BCLC Stage C Hepatocellular Carcinoma Trial in Hangzhou (TACE, Tilelizumab, Sorafenib)

Not yet recruiting
  • BCLC Stage C Hepatocellular Carcinoma
  • TACE
  • +2 more
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Aug 10, 2021

High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Tislelizumab Nab paclitaxel)

Recruiting
  • High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Tislelizumab Nab paclitaxel
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Jun 9, 2022

Colorectal Cancer, Liver Metastases Trial in Hangzhou (Experimental drug)

Recruiting
  • Colorectal Cancer
  • Liver Metastases
  • Experimental drug
  • Hangzhou, Zhejiang, China
    The Second Affiliated Hospital, Zhejiang University School of Me
Jun 5, 2022

Stage III, NSCLC Trial in Chengdu (tislelizumab)

Active, not recruiting
  • Stage III
  • Non-small Cell Lung Cancer
  • Chengdu, Sichuan, China
    University
Apr 28, 2021

High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Tislelizumab, Nab-paclitaxel)

Recruiting
  • High-Risk
  • Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Oct 22, 2021

Advanced Non-squamous NSCLC Trial in Beijing (TQB2450 injection, Tilelizumab injection, Anlotinib HCl capsule, Pemetrexed

Recruiting
  • Advanced Non-squamous Non-small Cell Lung Cancer
  • TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences Cancer Hospital
Apr 20, 2022

Biliary Tract Cancer, PD-1 Antibody, Gemox Trial in Shanghai (PD-1+Lenvatinib+GEMOX)

Recruiting
  • Biliary Tract Cancer
  • +3 more
  • Shanghai, China
    Zhongshan hospital
Dec 11, 2021

Gastric Cancer Trial in Shanghai (PD-1 inhibitor, Oxaliplatin, Capecitabine)

Recruiting
  • Gastric Cancer
  • PD-1 inhibitor
  • +6 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 1, 2021